A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1267-1273

  Huron, David R ^b   Gorre, Mercedes E ^c   Kraker, Alan J ^d   Sawyers, Charles L ^c   Rosen, Neal ^a   Moasser, Mark M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; IMATINIB; PD 166406; PD 179483; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; G1 PHASE; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIDINES; PYRIMIDINES;

EID: 0012907461     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Konopka, J. B., Watanabe, S. M., Singer, J. W., Collins, S. J., and Witte, O. N. Cell lines and clinical isolates derived from Phl-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc. Natl. Acad. Sci. USA, 82: 1810-1814, 1985.
2. Daley, G. Q., Van Etten, R. A., and Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (Wash. DC), 247: 824-830, 1990.
3. Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (Wash. DC), 247: 1079-1082, 1990.
4. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J., and Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.
5. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
6. Deininger, M. W., Goldman, J. M., Lydon, N., and Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90: 3691-3698, 1997.
7. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
8. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., and The International, S. T. I. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346: 645-652, 2002.
9. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042, 2001.
10. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001.
11. von Bubnoff, N., Schneller, F., Peschel, C., and Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet, 359: 487-491, 2002.
12. Deininger, M. W. N., Goldman, J. M., and Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood, 15: 3343-3356, 2000.
13. Danhauser-Riedl, S., Warmuth, M., Druker, B. J., Emmerich, B., and Hallek, M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res., 56: 3589-3596, 1996.
14. Dorsey, J. F., Jove, R., Kraker, A. J., and Wu, J. The pyrido[2, 3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res., 60: 3127-3131, 2000.
15. Kraker, A. J., Hartl, B. G., Amar, A., Barvian, M. R., Showalter, H. D., and Moore, C. W. Biochemical and cellular effects of c-src kinase-selective pyrido [2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol., 60: 885-898, 2000.
16. 2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements. Cytometry, 11: 813-821, 1990.
17. Dan, S., Naito, M., and Tsuruo, T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ., 5: 710-715, 1998.
18. Warmuth, M., Bergmann, M., Priess, A., Hauslmann, K., Emmerich, B., and Hallek, M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J. Biol. Chem., 272: 33260-33270, 1997.
19. Lionberger, J. M., Wilson, M. B., and Smithgall, T. E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J. Biol. Chem., 275: 18581-18585, 2000.
20. Roginskaya, V., Zuo, S., Caudell, E., Nambudiri, G., Kraker, A. J., and Corey, S. J. Therapeutic targeting of Src-kinase Lyn in myeloid leukemia cell growth. Leukemia (Baltimore), 13: 855-861, 1999.
21. Schindler, T., Bornmann, W., Pellicena, P., Miller, W., Clarkson, B., and Kuriyan, J. Structural Mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (Wash. DC), 289: 1938-1942, 2000.